Getagraph.com logo
S&P 500
(0.27%) 5 113.82 points
Dow Jones
(0.29%) 38 352 points
Nasdaq
(0.29%) 15 974 points
Oil
(-0.94%) $83.06
Gas
(5.51%) $2.03
Gold
(0.37%) $2 355.90
Silver
(0.42%) $27.65
Platinum
(3.97%) $958.75
USD/EUR
(-0.22%) $0.933
USD/NOK
(-0.41%) $10.98
USD/GBP
(-0.55%) $0.796
USD/RUB
(1.69%) $93.43

リアルタイムの更新： Talaris Therapeutics, [TALS]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
最終更新日時20 10月 2023 @ 05:00
25% discount on Stockinvest.us - Use code: Podcast

-0.73% $ 2.72

Live Chart Being Loaded With Signals

Commentary (20 10月 2023 @ 05:00):
Profile picture for Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders...

Stats
本日の出来高 303 484
平均出来高 142 922
時価総額 116.44M
EPS $-0.460 ( 2023-11-08 )
Last Dividend $1.512 ( 2023-10-19 )
Next Dividend $0 ( N/A )
P/E -1.563
ATR14 $0.122 (4.49%)
Insider Trading
Date Person Action Amount type
2023-12-13 Siegall Clay B Buy 20 000 Stock Option (Right to Buy)
2023-12-13 Siegall Clay B Buy 0
2023-11-17 Kulkarni Sandeep Chidambar Buy 4 000 Common Stock
2023-11-17 Thiara Parvinder Buy 1 000 Common Stock
2023-10-27 Castelein Caley Buy 15 800 Common Stock
INSIDER POWER
83.80
Last 89 transactions
Buy: 5 796 448 | Sell: 603 108

ボリューム 相関

長: 0.00 (neutral)
短: -0.17 (neutral)
Signal:(46.625) Neutral

Talaris Therapeutics, 相関

10 最も正の相関
MRNS0.86
NPCE0.842
ALR0.818
SMED0.817
EPZM0.815
BIS0.808
THRY0.807
LTRY0.807
CNCE0.805
LVO0.802
10 最も負の相関
WTBA-0.867
EGAN-0.854
ABST-0.853
CRNT-0.851
BNIXU-0.85
PIXY-0.834
CNDT-0.832
FREQ-0.823
VWE-0.817
UPC-0.813

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Talaris Therapeutics, 相関 - 通貨/商品

The country flag -0.42
( neutral )
The country flag -0.10
( neutral )
The country flag 0.00
( neutral )
The country flag -0.33
( neutral )
The country flag -0.78
( moderate negative )
The country flag 0.58
( weak )

Talaris Therapeutics, 財務諸表

Annual 2022
収益: $0
総利益: $0 (0.00 %)
EPS: $-16.66
FY 2022
収益: $0
総利益: $0 (0.00 %)
EPS: $-16.66
FY 2021
収益: $0.00
総利益: $0.00 (0.00 %)
EPS: $-2.26
FY 2020
収益: $0.00
総利益: $0.00 (0.00 %)
EPS: $-1.070

Financial Reports:

No articles found.

Talaris Therapeutics, Dividends

(Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$1.512
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Talaris Therapeutics, Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $1.512 2023-10-19
Last Dividend $1.512 2023-10-19
Next Dividend $0 N/A
Payout Date 2023-10-20
Next Payout Date N/A
# dividends 1 --
Total Paid Out $1.512 --
Avg. Dividend % Per Year 46.23% --
Score 4.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-04-29)
$3.02 Estimate 2.50 %
Dividend Stability
0.20 Very Poor
Dividend Score
4.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2023 $1.512 138.70%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-0.3821.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3641.500-5.16-7.74[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM18.640.80010.008.00[1 - 3]
quickRatioTTM18.140.80010.008.00[0.8 - 2.5]
cashRatioTTM8.281.50010.0010.00[0.2 - 2]
debtRatioTTM0.00420-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM-17.911.000-7.75-7.75[3 - 30]
operatingCashFlowPerShareTTM-12.282.00-4.09-8.19[0 - 30]
freeCashFlowPerShareTTM-12.472.00-6.24-10.00[0 - 20]
debtEquityRatioTTM0.00444-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-82.751.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score-1.667

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.2021.000-0.1210[1 - 100]
returnOnEquityTTM-0.3642.50-3.32-7.74[0.1 - 1.5]
freeCashFlowPerShareTTM-12.472.00-4.16-10.00[0 - 30]
dividendYielPercentageTTM55.581.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM-12.282.00-4.09-8.19[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.003921.500-3.360[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-2.25

Talaris Therapeutics,

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。